Lans Holdings Enters into Binding LOI to Acquire Global Stem Cells Group
May 28, 2019 08:00 ET
|
Lans Holdings Inc.
MIAMI, FL, May 28, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Lans Holdings Inc. (OTCPink: LAHO) is pleased to announce that it has entered into a binding letter of intent to acquire 100%...
International Stem Cell Corporation Announces Operating Results for the Quarter Ended March 31, 2019
May 17, 2019 08:30 ET
|
International Stem Cell Corporation
CARLSBAD, Calif., May 17, 2019 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage...
3D Cell Culture Market To Reach USD 1.99 Billion By 2026 | Reports And Data
April 25, 2019 13:24 ET
|
Reports And Data
The government and non-government investments in cancer research & development, coupled with the large scale end uses of stem cell research are influencing the market growth. Market Size – USD...
International Stem Cell Corporation Announces 2018 Fourth Quarter and Year-End Results
April 15, 2019 08:30 ET
|
International Stem Cell Corporation
CARLSBAD, Calif., April 15, 2019 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQX: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage...
Hemostemix Announces Appointment of Experienced Chief Medical Officer & President
April 01, 2019 08:30 ET
|
Hemostemix Inc.
CALGARY, Alberta, April 01, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF) is pleased to announce that Dr. Alan J. Jacobs, M.S.EE, M.D,...
Hemostemix Announces UC Davis Health Added as a Trial Site for Phase II Clinical Trial
February 25, 2019 08:30 ET
|
Hemostemix Inc.
CALGARY, Alberta, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB:HMTXF) is pleased to announce that it has received all approvals from UC...
Hemostemix Provides Highlights of 2018 Accomplishments
January 17, 2019 08:30 ET
|
Hemostemix Inc.
CALGARY, Alberta, Jan. 17, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF) is pleased to provide the following corporate update on...
Hemostemix Announces Two Additional Sites Enrolled in Phase II Clinical Trial
January 03, 2019 08:00 ET
|
Hemostemix Inc.
CALGARY, Alberta, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB:HMTXF) is pleased to announce that it has received all approvals from two...
Hemostemix Announces Development of an ACP-01 Allogeneic Process and Initiation of R&D for Autologous NCP-01 Neural Cellular Precursors
November 09, 2018 08:30 ET
|
Hemostemix Inc.
CALGARY, Alberta, Nov. 09, 2018 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF) is pleased to provide the following update on its research and...
Hemostemix Announces Important Manufacturing Process Refinements
November 08, 2018 08:30 ET
|
Hemostemix Inc.
CALGARY, Alberta, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF) is pleased to announce that is has completed refinements to its...